

Press Information

Series production of BIOCERAM AZUL® in Waiblingen


The highly automated Industry 4.0 production creates additional capacity for international implant manufacturers and strengthens Kyocera's presence in the market for ceramic ball heads.

Kyoto/Esslingen, 10th September 2026. KYOCERA Fineceramics Medical GmbH has begun series production of ceramic ball heads made from BIOCERAM AZUL® at its Waiblingen site in Germany. This marks an important milestone for the company as it expands its activities in the field of endoprosthesis. Initial customer orders have already been manufactured and delivered from Waiblingen.

Highly automated manufacturing of ceramic ball heads

The new production facility in Waiblingen was specifically designed for the industrial manufacturing of ceramic ball heads and is based on a production concept consistently aligned with Industry 4.0 principles. Largely digitalised and automated processes enable paperless control and documentation of all manufacturing steps. This ensures a high process reliability, complete traceability, and consistently high quality. At the same time, this flexible and scalable production is essential for reliably meeting growing international customer demands.

"The start of series production in Waiblingen marks an important milestone for our company. With our highly automated and digitalised manufacturing, we are creating the conditions to produce ceramic ball heads efficiently and to a consistently high standard of quality for international customers," says Uwe Kemmer, Managing Director of KYOCERA Fineceramics Medical GmbH.



Kyocera's Industry 4.0 production facility in Waiblingen

BIOCERAM AZUL®: Kyocera's high-performance ceramic material for ceramic ball heads

At the heart of the new series production is BIOCERAM AZUL®. The material builds on the company's decades of experience in development and manufacture of ceramic components for medical applications.

Kyocera has been developing ceramic solutions for the medical technology sector for more than five decades. BIOCERAM AZUL® has been in use on the Japanese market since 2015. With the current series production in Waiblingen, Kyocera is now establishing the industrial foundation for further international expansion and collaboration with implant manufacturers worldwide.



BIOCERAM AZUL® Ceramic balls for orthopedic implants

"With BIOCERAM AZUL®, we combine our extensive expertise in high-performance medical ceramics with state-of-the-art manufacturing in Germany. The start of series production is therefore far more than just a production milestone: It lays the foundation for the further international expansion of our business in ceramic components for endoprosthetics," says Dr Fabian Preuß, Managing Director of KYOCERA Fineceramics Medical GmbH.

First customer orders already delivered

Since the establishment of KYOCERA Fineceramics Medical GmbH in 2024, the company has continuously expanded its engagement with international manufacturers of orthopaedic implants. Numerous customers and potential partners have already visited the new production facility in Waiblingen to learn first-hand about the manufacturing concept and BIOCERAM AZUL®.

With the production and delivery of the first customer orders, this market expansion has now reached another important milestone. At the same time, Kyocera is in discussions with other implant manufacturers regarding the use of ceramic ball heads from Waiblingen.



The new production facility of KYOCERA Fineceramics Medical GmbH in Waiblingen

International exchange with the orthopaedic community

The new series production and BIOCERAM AZUL® will also be the focus of Kyocera's upcoming international congress activities.

The first event will be the annual congress of the [international society for technology in arthroplasty \(ISTA\)](#), taking place from 15 to 18 September 2026 at BMW Welt in Munich, Germany (Kyocera Booth # 10).

There, Kyocera will host a scientific symposium featuring international experts in orthopaedics and biomechanics, led by Professor Javad Parvizi.

Other events include the [Deutscher Kongress für Orthopädie und Unfallchirurgie \(DKOU, German congress for orthopaedics and trauma surgery\)](#) from 20 to 23 October 2026 in Berlin, Germany (Kyocera Booth # B112) and the annual meeting of the [American association of hip and knee surgeons \(AAHKS\)](#) from 5 to 8 November 2026 in Dallas, Texas (Kyocera Booth # 1602).



These congresses offer Kyocera the opportunity to further deepen its dialogue with implant manufacturers, surgeons, scientists, and other partners regarding ceramic materials, modern manufacturing technologies and future requirements in endoprosthesis.

The press material is available for download via the following link:

<https://spgroup.box.com/s/pnpm8hx7444xvrczzbv90qm9womybrd4>



For more information on Kyocera: www.kyocera-medical.de

About Kyocera

Kyocera has been successful in Europe for over 50 years. From its European headquarters in Esslingen am Neckar, KYOCERA Europe GmbH operates 27 sites including manufacturing facilities, with products ranging from fine ceramics, automotive, semiconductor and optical components to components for medical products, industrial tools, LCDs, touch solutions, industrial printing components, and consumer goods such as kitchen and office products.

Kyocera's high-performance ceramic products are produced and distributed by [KYOCERA Fineceramics Europe GmbH](#), a subsidiary of KYOCERA Europe GmbH. [KYOCERA Fineceramics Medical GmbH](#) is part of KYOCERA Fineceramics Europe GmbH and will start shipping its products for the medical sector in the first quarter of 2026. The Kyocera Group is one of the world's leading providers of high-performance ceramic components for the technology industry, offering over 200 different ceramic materials, as well as state-of-the-art technologies and services tailored to the specific needs of each market.

KYOCERA Europe GmbH is a company of the [KYOCERA Corporation](#) headquartered in Kyoto/Japan, a renowned supplier in semiconductor, industrial and automotive components as well as electronic components, printing and multifunction systems, smart energy systems, and communications technology. Kyocera is one of the most experienced technology producers, with more than 65 years of industry expertise. The Kyocera Group comprises 279 subsidiaries (31 March 2026). With around 73,800 employees, Kyocera generated net annual sales of around EUR 11.83 billion in the 2025/2026 fiscal year.

Kyocera is ranked 1,123 on Forbes magazine's 'Global 2000' list for 2025 and ranked as 'The 100 Most Sustainably Managed Companies in the World' according to the Wall Street Journal. For the fourth time Kyocera has received an A ranking on the CDP A List for their performance on climate change. Kyocera has also received a silver rating in the EcoVadis Sustainability Survey and was acknowledged as a 'Top 100 Global Innovator 2026' for the tenth time by Clarivate, being one of the world's leading innovators.

Kyocera also takes an active interest in cultural affairs. The Kyoto Prize, a prominent international award, is presented each year by the Inamori Foundation – established by Kyocera founder Dr Kazuo Inamori – to individuals worldwide who have contributed significantly to the scientific, cultural, and spiritual betterment of humankind (equivalent to approximately €539,000 per prize category).

Contact

KYOCERA Europe GmbH
Andrea Berlin
Fritz-Müller-Straße 27
73730 Esslingen / Germany
Tel: +49 711/93 93 48 96
Mobil: +49 151 16 33 07 93
E-Mail: PR@kyocera.de
uk.kyocera.com